Nasdaq · CIK 0001816736
IRON Disc Medicine, Inc.
Insider trading from SEC Form 4. Last filing 25 d ago. Close $62.06 on Oct 9, 2026, +11% from the 52-week low and -34% from the high.
Last 90 days
Net insider value
-$6.4M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$6.4M by 1 insider
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
IRONOct 9, 2026 · close 62.06
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Disc Medicine, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Kevin Bitterman director sell | $1.9M 27,136 shares | -100% | - | |
| 6Weak | Kevin Bitterman director sell | $135k 1,689 shares | -1% | - | |
| 25Weak | Kevin Bitterman director sell | $4.4M 54,496 shares | -16% | - | |
| 37Weak | Mona Ashiya director sell | $310k 5,738 shares | -1% | - | |
| 37Weak | Orbimed Advisors LLC director sell | $310k 5,738 shares | -1% | - | |
| 53Moderate | Mona Ashiya director sell | $2.8M 52,429 shares | -10% | - | |
| 53Moderate | Orbimed Advisors LLC director sell | $2.8M 52,429 shares | -10% | - | |
| 68Notable | Mona Ashiya director sell | $17M 312,384 shares | -51% | - | |
| 68Notable | Orbimed Advisors LLC director sell | $17M 312,384 shares | -51% | - | |
| 54Moderate | John D Quisel Chief Executive Officer sell | $304k 5,574 shares | -3% | - | |
| 48Moderate | Jean M. Franchi Chief Financial Officer sell | $171k 3,136 shares | -4% | - | |
| 44Moderate | Jonathan Yen-Wen Yu Chief Operating Officer sell | $88k 1,610 shares | -4% | - | |
| 39Weak | William Jacob Savage Chief Medical Officer sell | $89k 1,638 shares | -2% | - | |
| 38Weak | Rahul Khara Chief Legal Officer sell | $63k 1,161 shares | -3% | - | |
| 41Moderate | Pamela Stephenson Chief Commercial Officer sell | $171k 3,137 shares | -4% | - | |
| 6Weak | Rahul Khara Chief Legal Officer sell | $417k 7,500 shares | -35% | - | |
| 15Weak | Rahul Khara Chief Legal Officer sell | $471k 7,500 shares | -35% | - | |
| 25Weak | John D Quisel Chief Executive Officer sell | $806k 13,012 shares | -15% | - | |
| 28Weak | John D Quisel Chief Executive Officer sell | $1.3M 19,820 shares | -22% | - | |
| 26Weak | John D Quisel Chief Executive Officer sell | $844k 12,791 shares | -15% | - | |
| 26Weak | William Richard White director sell | $126k 1,957 shares | -100% | - | |
| 22Weak | William Jacob Savage Chief Medical Officer sell | $928k 14,183 shares | -26% | - | |
| 12Weak | William Jacob Savage Chief Medical Officer sell | $546k 9,158 shares | -18% | - | |
| 25Weak | William Richard White director sell | $428k 7,337 shares | -3650% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | John D Quisel Chief Executive Officer | MOption exercise Common Stock | +36,000 | $1.01 | $36k | 262,064 | 25 d ago |
| Sep 15, 2026 | John D Quisel Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative | -36,000 | $0.00 | $0 | 150,120 | 25 d ago |
| Sep 11, 2026 | Kevin Bitterman director | MOption exercise Common Stock | +7,136 | $45.69 | $326k | 7,136 | 26 d ago |
| Sep 11, 2026 | Kevin Bitterman director | MOption exercise Common Stock | +10,000 | $38.85 | $389k | 17,136 | 26 d ago |
| Sep 11, 2026 | Kevin Bitterman director | MOption exercise Common Stock | +10,000 | $50.86 | $509k | 27,136 | 26 d ago |
| Sep 11, 2026 | Kevin Bitterman director | SOpen-market sale Common Stock | -27,136 | $70.11 | $1.9M | 0 | 26 d ago |
| Sep 11, 2026 | Kevin Bitterman director | MOption exercise Stock Option (Right to Buy)derivative | -7,136 | $0.00 | $0 | 0 | 26 d ago |
| Sep 11, 2026 | Kevin Bitterman director | MOption exercise Stock Option (Right to Buy)derivative | -10,000 | $0.00 | $0 | 0 | 26 d ago |
| Sep 11, 2026 | Kevin Bitterman director | MOption exercise Stock Option (Right to Buy)derivative | -10,000 | $0.00 | $0 | 0 | 26 d ago |
| Sep 4, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -912 | $79.96 | $73k | 318,866 | 32 d ago |
| Sep 4, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -759 | $79.96 | $61k | 312,230 | 32 d ago |
| Sep 4, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -18 | $79.96 | $1,439 | 13,427 | 32 d ago |
| Sep 1, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -70 | $79.95 | $5,597 | 349,140 | 38 d ago |
| Sep 1, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -58 | $79.95 | $4,637 | 337,427 | 38 d ago |
| Sep 1, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1 | $79.95 | $80 | 14,012 | 38 d ago |
| Sep 2, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -26,542 | $80.17 | $2.1M | 322,598 | 38 d ago |
| Sep 2, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -22,090 | $80.17 | $1.8M | 315,337 | 38 d ago |
| Sep 2, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -511 | $80.17 | $41k | 13,501 | 38 d ago |
| Sep 2, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -10 | $80.98 | $810 | 322,588 | 38 d ago |
| Sep 2, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -9 | $80.98 | $729 | 315,328 | 38 d ago |
| Sep 2, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2 | $80.98 | $162 | 13,499 | 38 d ago |
| Sep 3, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,810 | $79.98 | $225k | 319,778 | 38 d ago |
| Sep 3, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,339 | $79.98 | $187k | 312,989 | 38 d ago |
| Sep 3, 2026 | Kevin Bitterman director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -54 | $79.98 | $4,319 | 13,445 | 38 d ago |
| Mar 24, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -1,956 | $54.11 | $106k | 482,308 | Mar 26, 2025 |
| Mar 24, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -1,956 | $54.11 | $106k | 482,308 | Mar 26, 2025 |
| Mar 24, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -3,026 | $54.11 | $164k | 746,171 | Mar 26, 2025 |
| Mar 24, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -3,026 | $54.11 | $164k | 746,171 | Mar 26, 2025 |
| Mar 24, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -756 | $54.11 | $41k | 186,541 | Mar 26, 2025 |
| Mar 24, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -756 | $54.11 | $41k | 186,541 | Mar 26, 2025 |
| Mar 19, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -13,517 | $54.02 | $730k | 488,617 | Mar 21, 2025 |
| Mar 19, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -13,517 | $54.02 | $730k | 488,617 | Mar 21, 2025 |
| Mar 19, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -20,911 | $54.02 | $1.1M | 755,933 | Mar 21, 2025 |
| Mar 19, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -20,911 | $54.02 | $1.1M | 755,933 | Mar 21, 2025 |
| Mar 19, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -5,228 | $54.02 | $282k | 188,981 | Mar 21, 2025 |
| Mar 19, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -5,228 | $54.02 | $282k | 188,981 | Mar 21, 2025 |
| Mar 20, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -941 | $54.01 | $51k | 487,676 | Mar 21, 2025 |
| Mar 20, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -941 | $54.01 | $51k | 487,676 | Mar 21, 2025 |
| Mar 20, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -1,457 | $54.01 | $79k | 754,476 | Mar 21, 2025 |
| Mar 20, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -1,457 | $54.01 | $79k | 754,476 | Mar 21, 2025 |
| Mar 20, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -364 | $54.01 | $20k | 188,617 | Mar 21, 2025 |
| Mar 20, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -364 | $54.01 | $20k | 188,617 | Mar 21, 2025 |
| Mar 21, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -3,412 | $54.00 | $184k | 484,264 | Mar 21, 2025 |
| Mar 21, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -3,412 | $54.00 | $184k | 484,264 | Mar 21, 2025 |
| Mar 21, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -5,279 | $54.00 | $285k | 749,197 | Mar 21, 2025 |
| Mar 21, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -5,279 | $54.00 | $285k | 749,197 | Mar 21, 2025 |
| Mar 21, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -1,320 | $54.00 | $71k | 187,297 | Mar 21, 2025 |
| Mar 21, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -1,320 | $54.00 | $71k | 187,297 | Mar 21, 2025 |
| Mar 10, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -68,766 | $54.29 | $3.7M | 539,845 | Mar 12, 2025 |
| Mar 10, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -68,766 | $54.29 | $3.7M | 539,845 | Mar 12, 2025 |
| Mar 10, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -106,384 | $54.29 | $5.8M | 835,185 | Mar 12, 2025 |
| Mar 10, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -106,384 | $54.29 | $5.8M | 835,185 | Mar 12, 2025 |
| Mar 10, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -26,596 | $54.29 | $1.4M | 208,795 | Mar 12, 2025 |
| Mar 10, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -26,596 | $54.29 | $1.4M | 208,795 | Mar 12, 2025 |
| Mar 10, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -136 | $55.01 | $7,481 | 539,709 | Mar 12, 2025 |
| Mar 10, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -136 | $55.01 | $7,481 | 539,709 | Mar 12, 2025 |
| Mar 10, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -211 | $55.01 | $12k | 834,974 | Mar 12, 2025 |
| Mar 10, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -211 | $55.01 | $12k | 834,974 | Mar 12, 2025 |
| Mar 10, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -53 | $55.01 | $2,916 | 208,742 | Mar 12, 2025 |
| Mar 10, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -53 | $55.01 | $2,916 | 208,742 | Mar 12, 2025 |
| Mar 11, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -9,222 | $54.01 | $498k | 530,487 | Mar 12, 2025 |
| Mar 11, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -9,222 | $54.01 | $498k | 530,487 | Mar 12, 2025 |
| Mar 11, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -14,267 | $54.01 | $771k | 820,707 | Mar 12, 2025 |
| Mar 11, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -14,267 | $54.01 | $771k | 820,707 | Mar 12, 2025 |
| Mar 11, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -3,567 | $54.01 | $193k | 205,175 | Mar 12, 2025 |
| Mar 11, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -3,567 | $54.01 | $193k | 205,175 | Mar 12, 2025 |
| Mar 12, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -603 | $55.05 | $33k | 529,884 | Mar 12, 2025 |
| Mar 12, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -603 | $55.05 | $33k | 529,884 | Mar 12, 2025 |
| Mar 12, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -933 | $55.05 | $51k | 819,774 | Mar 12, 2025 |
| Mar 12, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -933 | $55.05 | $51k | 819,774 | Mar 12, 2025 |
| Mar 12, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -233 | $55.05 | $13k | 204,942 | Mar 12, 2025 |
| Mar 12, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -233 | $55.05 | $13k | 204,942 | Mar 12, 2025 |
| Mar 12, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -27,750 | $54.44 | $1.5M | 502,134 | Mar 12, 2025 |
| Mar 12, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -27,750 | $54.44 | $1.5M | 502,134 | Mar 12, 2025 |
| Mar 12, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -42,930 | $54.44 | $2.3M | 776,844 | Mar 12, 2025 |
| Mar 12, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -42,930 | $54.44 | $2.3M | 776,844 | Mar 12, 2025 |
| Mar 12, 2025 | Mona Ashiya director | SOpen-market sale Common Stockindirect: See Footnotes | -10,733 | $54.44 | $584k | 194,209 | Mar 12, 2025 |
| Mar 12, 2025 | Orbimed Advisors LLC director | SOpen-market sale Common Stockindirect: See Footnotes | -10,733 | $54.44 | $584k | 194,209 | Mar 12, 2025 |
| Feb 18, 2025 | John D Quisel Chief Executive Officer | SOpen-market sale Common Stock | -5,574 | $54.58 | $304k | 154,828 | Feb 20, 2025 |
| Feb 18, 2025 | Jean M. Franchi Chief Financial Officer | SOpen-market sale Common Stock | -3,136 | $54.58 | $171k | 69,530 | Feb 20, 2025 |
| Feb 18, 2025 | Jonathan Yen-Wen Yu Chief Operating Officer | SOpen-market sale Common Stock | -1,610 | $54.58 | $88k | 40,555 | Feb 20, 2025 |
| Feb 18, 2025 | William Jacob Savage Chief Medical Officer | SOpen-market sale Common Stock | -1,638 | $54.58 | $89k | 68,498 | Feb 20, 2025 |
| Feb 18, 2025 | Rahul Khara Chief Legal Officer | SOpen-market sale Common Stock | -1,161 | $54.58 | $63k | 37,583 | Feb 20, 2025 |
| Feb 18, 2025 | Pamela Stephenson Chief Commercial Officer | SOpen-market sale Common Stock | -3,137 | $54.58 | $171k | 69,529 | Feb 20, 2025 |
| Feb 10, 2025 | John D Quisel Chief Executive Officer | AGrant or award Common Stock | +78,337 | $0.00 | $0 | 160,402 | Feb 12, 2025 |
| Feb 10, 2025 | Jean M. Franchi Chief Financial Officer | AGrant or award Common Stock | +36,000 | $0.00 | $0 | 72,666 | Feb 12, 2025 |
| Feb 10, 2025 | Jonathan Yen-Wen Yu Chief Operating Officer | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 42,165 | Feb 12, 2025 |
| Feb 10, 2025 | Rahul Khara Chief Legal Officer | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 38,035 | Feb 12, 2025 |
| Feb 10, 2025 | Pamela Stephenson Chief Commercial Officer | AGrant or award Common Stock | +36,000 | $0.00 | $0 | 72,666 | Feb 12, 2025 |
| Feb 3, 2025 | William Jacob Savage Chief Medical Officer | MOption exercise Common Stock | +4,233 | $2.65 | $11k | 44,638 | Feb 12, 2025 |
| Feb 10, 2025 | John D Quisel Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +117,505 | $0.00 | $0 | 117,505 | Feb 12, 2025 |
| Feb 10, 2025 | Jean M. Franchi Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Feb 12, 2025 |
| Feb 10, 2025 | Jonathan Yen-Wen Yu Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Feb 12, 2025 |
| Feb 10, 2025 | Rahul Khara Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Feb 12, 2025 |
| Feb 3, 2025 | William Jacob Savage Chief Medical Officer | MOption exercise Common Stock | +1,498 | $2.65 | $3,970 | 46,136 | Feb 12, 2025 |
| Feb 10, 2025 | Pamela Stephenson Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Feb 12, 2025 |
| Feb 10, 2025 | William Jacob Savage Chief Medical Officer | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 70,136 | Feb 12, 2025 |
| Feb 3, 2025 | William Jacob Savage Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative | -4,233 | $0.00 | $0 | 0 | Feb 12, 2025 |
| Feb 3, 2025 | William Jacob Savage Chief Medical Officer | MOption exercise Stock Option (Right to Buy)derivative | -1,498 | $0.00 | $0 | 0 | Feb 12, 2025 |
| Feb 10, 2025 | William Jacob Savage Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +36,000 | $0.00 | $0 | 36,000 | Feb 12, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Mona Ashiyadirector
- Kevin Bittermandirector
- Jean M. FranchiChief Financial Officer
- Rahul KharaChief Legal Officer
- Orbimed Advisors LLCdirector, owner
- John D QuiselChief Executive Officer
- William Jacob SavageChief Medical Officer
- Pamela StephensonChief Commercial Officer
- William Richard Whitecfo, officer, director
- Jonathan Yen-Wen YuChief Operating Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.